CF PharmTech, Inc. Raises USD $65 Million to Accelerate the Development of Company's Inhalation Products and Manufacturing Capacity to Global Market

จันทร์ 28 สิงหาคม 2560 เวลา 10:44 น.

          CF PharmTech, Inc. ("CF PharmTech"), a leading specialty pharmaceutical company that develops and manufactures inhalation products, announced today that it has raised $65M in a Series D financing. Future Industry Investment Fund, a private equity fund managed by SDIC Fund Management Corporation Limited ("SDIC Fund Management"), led the financing along with other prestigious healthcare investment groups in China.

          https://photos.prnasia.com/prnvar/2CF PharmTech17CF PharmTech825/1927664-1

          CF PharmTech, founded by seasoned industry experts and entrepreneurs with a successful track record in the US pharmaceutical industry, is focused on the development, manufacturing and commercialization of high-quality inhalation products for the global market. Since its inception, CF PharmTech has established state-of-art research and manufacturing facilities to advance its product development. This new round of investment will not only expedite the submission of its product pipeline to meet regulatory approvals in China and abroad, but also expand its CDMO service to international clients.

          Mr. Hai Lu, Managing Director of SDIC Fund Management, commented: "Drug delivery via pulmonary route bears significant technical challenges and it takes extraordinary effort to bring inhalation products to the market. CF PharmTech's high caliber team has proved their ability to attract top industry talents to develop inhalation products for the global market. We are confident that they will achieve their business mission in the near future."

          CF PharmTech, headquartered in Suzhou, China, develops metered dose inhaler, inhalation powder, nasal spray and blow-fill-seal products. It has established high-quality research and manufacturing environments to be compliant with US, EU and Chinese regulations. CF PharmTech aims to provide quality and cost-effective inhalation products for domestic market, and seeks strategic partnerships to co-develop and commercialize its products globally.

          About SDIC Fund Management Corporation Limited

          Established in July 2CF PharmTechCF PharmTech9, SDIC Fund Management Corporation Limited is an independent, professional private equity firm. It currently manages and advises more than RMB 5CF PharmTech billion of capital for a wide range of institutional investors including financial institutions, pension funds, and state-owned and private capital. SDIC Fund Management Corporation Limited is one of the largest, professional private equity fund managers in China. The core strategy of SDIC Fund Management is to invest in market leading companies with attractive growth prospects and outstanding management teams.

          Photo- https://photos.prnasia.com/prnh/2CF PharmTech17CF PharmTech825/1927664-1

ข่าวCF PharmTech+o:prncnวันนี้

ChuanQi IP, "MIR2M: The Grandmaster" Release Airdrop Event in Progress

3rd Mobile Title Based on "The Legend of Mir 2" Universe Features Various Contents such as PvP Battles, Boss Dungeons, Guild System Commemorative Events Include Mission Completion, Gameplay Review Video Production ChuanQi IP, a subsidiary of WEMADE (CEO: Henry Chang), has officially released the blockchain-based idle martial arts RPG, "MIR2M: The Grandmaster," today (2nd). "MIR2M: The Grandmaster" is the third title in the MIR2M series. Based on "The Legend of Mir 2" universe, it tells the story

02 กุมภาพันธ์ 2567 09:00 น.

ฉวนฉี ไอพี จัดกิจกรรมแอร์ดรอปฉลองการเปิดตัวเกม "MIR2M: The Grandmaster" — เกมมือถือเกมที่ 3 ในจักรวาล "The Legend of Mir 2" อัดแน่นด้วยคอนเทนต์หลากหลาย ทั... ก.พ. 67

CF PharmTech จับมือ Chengdu Shangyi เปิดตัว "โปรแกรมฟื้นฟูสุขภาพที่บ้านสำหรับผู้ป่วยโควิด-19 ที่รักษาหายแล้ว" พร้อมปล่อยแอป "R Plus Health" ให้ใช้ฟรีทั่วโลก — CF PharmTec... ก.พ. 64

CF PharmTech and Chengdu Shangyi Launch the "Home-Based Recovery Program for Discharged Covid-19 Patients" and Announce Today's Global Release of the "R Plus Health" Free App — CF PharmTec... ก.พ. 64

CF PharmTech ปิดระดมทุน Series F วงเงิน 50 ล้านดอลลาร์ เร่งผลิตยาสูดพ่นออกสู่ตลาด — CF PharmTech, Inc. ประกาศว่า บริษัทได้รับเงินลงทุน 50 ล้านดอลลาร์สหรัฐ... ก.ค. 63

CF PharmTech, Inc. Closes a US $50M Series F Financing to Accelerate the Commercialization of its Inhalation Products. — CF PharmTech, Inc. ("CF PharmTech... ก.ค. 63

CF PharmTech ปิดระดมทุนวงเงิน 90 ล้านดอลลาร์สหรัฐ มุ่งพัฒนายารักษาโรคระบบทางเดินหายใจ — CF PharmTech, Inc. บริษัทเภสัชกรรมที่มีวิสัยทัศน์เพื่อพัฒนาและผลิต... ม.ค. 63

CF PharmTech Closes US$ 90 Million Financing Round to Accelerate Global Development of Respiratory Drugs — CF PharmTech, Inc., a pharmaceutical company wi... ม.ค. 63

CF PharmTech ระดมทุน 65 ล้านดอลลาร์ เพื่อเร่งพัฒนาผลิตภัณฑ์ยาสูดพ่นและขยายกำลังผลิตสู่ตลาดโลก

CF PharmTech, Inc. ("CF PharmTech") บริษัทเวชภัณฑ์เฉพาะทางชั้นนำผู้พัฒนาและผลิตผลิตภัณฑ์ยาสูดพ่น ประกาศว่า บริษัทระดมทุนได้ 65 ล้านดอลลาร์สหรัฐในการระดมทุนรอบ Series D โดยมี Future Industry Investment Fund... ส.ค. 60

CF PharmTech, Inc. Raises USD $65 Million to Accelerate the Development of Company's Inhalation Products and Manufacturing Capacity to Global Market

CF PharmTech, Inc. ("CF PharmTech"), a leading specialty pharmaceutical company that develops and manufactures inhalation products, announced today that... ส.ค. 60